KOSDAQIT & Software108860

Selvas AI

₩7,170▲ 0.56%2026-11-18 close
Market Cap
₩193B
Turnover
₩1B
Volume
140K
Shares out.
26.9M
PER
—
PBR
1.9×
EPS
-₩185
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit turns positive, net losses persist

Selvas AI's revenue rose for three consecutive years to KRW 114.8 billion in 2025, yet attributable net losses of KRW 6 billion extended a three-year loss streak, so whether operating profit carries through to the bottom line is the key question.

  1. 1

    Revenue rose for three straight years from 2023 through 2025, reaching KRW 114.8 billion in 2025. The 112.1% jump in 2024 coincides with the consolidation of MEDIANA, which was acquired in January 2024.

  2. 2

    The operating margin fell from 9.8% in 2022 to 0.7% in 2024 and recovered slightly to 1.3% in 2025. Operating profit itself rose 85.3% to KRW 1.48 billion in 2025.

  3. 3

    Attributable net losses have continued for three consecutive years since 2023, widening to KRW 6 billion in 2025.

  4. 4

    Operating profit was positive in the second and third quarters of 2026, while attributable net losses appeared in both quarters.

  5. 5

    Voice AI added a reference case in November 2026 with the on-device speech synthesis launch at YES24, and subsidiary MEDIANA's integrated monitoring solution has surpassed 6,000 beds supplied.

02

Business structure

Selvas AI is an AI company founded in 1999 and listed on KOSDAQ in 2009. It supplies AI engines and solutions built on speech recognition (STT), speech synthesis (TTS), handwriting recognition and OCR.

A trade publication reported in May 2026 that AI-based technology (speech, OCR and handwriting) accounts for about 40% of the business, application solutions for medical and healthcare about 50%, and electronic dictionaries about 10%, with medical making up more than half.

The medical arm centers on the consolidated subsidiary MEDIANA, which makes and sells patient monitors (PMD), automated external defibrillators (AED) and other devices.

MEDIANA reported 2025 revenue of KRW 64.8 billion and operating profit of KRW 5.65 billion in February 2026, and in August 2026 it reported first-half 2026 consolidated revenue of KRW 37.2 billion and operating profit of KRW 4.6 billion.

In September 2026 its cumulative supply of integrated monitoring solutions passed 6,000 beds. On the voice side, the company supplies the AI medical voice recording product SELVAS MediVoice to many departments at tertiary hospitals, and the SELVAS deepTTS speech synthesis engine to e-book platforms.

In November 2026 it commercialized on-device cross-lingual speech synthesis at YES24's e-book app. It is also extending voice interfaces to financial kiosks, including Woori Bank's STM, and to an Incheon International Airport guide robot, pushing into physical AI.

The competitive field mixes large IT platform companies with specialist voice firms, and at KRW 114.8 billion in consolidated revenue Selvas AI is small next to the large IT groups.

Beyond its own engines, the company uses external large language models and is developing small language models specialized for medical and public use, as it said in early 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.8B₩1B4.0%
2025Q4₩34.5B₩800M2.3%
2026Q1₩26.6B-₩400M−1.4%
2026Q2₩33.3B₩1.8B5.3%
2026Q3₩33.9B₩1.9B5.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩50.9B₩5B₩6.6B9.8%12.1%49.0%
2023₩53B₩4.1B-₩2.6B7.7%−1.9%14.4%
2024₩112.5B₩800M-₩5.8B0.7%−4.8%18.7%
2025₩114.8B₩1.5B-₩6B1.3%−5.5%18.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue went from KRW 50.9 billion in 2022 to KRW 53 billion in 2023 (up 4.2%), KRW 112.5 billion in 2024 (up 112.1%) and KRW 114.8 billion in 2025 (up 2.1%). It rose for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022–2025 span.

The 2024 surge coincides with the period when MEDIANA, acquired in January 2024, entered consolidated results. Operating profit was KRW 4.99 billion in 2022, KRW 4.09 billion in 2023 (down 18.1%), KRW 800 million in 2024 (down 80.4%) and KRW 1.48 billion in 2025 (up 85.3%).

The operating margin moved from 9.8% to 7.7%, bottomed at 0.7% in 2024 and recovered slightly to 1.3% in 2025. The company attributed 2025 improvement to higher overseas sales at MEDIANA and a better cost structure.

Attributable net income swung from KRW 6.6 billion in 2022 to a net loss of KRW 2.55 billion in 2023, then widened to a net loss of KRW 5.81 billion in 2024 and KRW 6 billion in 2025.

Net income including non-controlling interests was a net loss of KRW 4.34 billion in 2025, smaller than the attributable loss, which means non-controlling holders earned a profit equal to the gap.

Operating cash flow reached KRW 9.4 billion in 2025, the highest since 2022, and the debt-to-equity ratio fell from 49.0% in 2022 to 18.2% in 2025. Total equity at year-end 2025 was KRW 259.9 billion, of which attributable equity was KRW 110.1 billion.

Quarterly revenue went from KRW 25.8 billion in the third quarter of 2025 to KRW 34.5 billion in the fourth quarter (up 33.6% from the prior quarter), fell to KRW 26.6 billion in the first quarter of 2026 (down 22.8%), then recovered to KRW 33.3 billion in the second quarter and KRW 33.9 billion in the third.

Operating profit turned from KRW 780 million in the fourth quarter of 2025 to an operating loss of KRW 370 million in the first quarter of 2026, then returned to profit at KRW 1.78 billion in the second quarter and KRW 1.86 billion in the third.

Attributable results were a net profit of KRW 502 million in the first quarter of 2026, then net losses of KRW 631 million in the second and KRW 1.15 billion in the third.

Operating profit in the black alongside attributable net losses points to a large effect from items below operating profit, which the annual report should detail.

05

Industry analysis

The voice AI market is split across e-book narration, financial kiosks, medical records and robot interfaces. The company is described as ranking first in domestic speech synthesis market share, and it has weighted its focus toward medical and physical AI.

It launched the integrated AI language-assessment product SELVAS SpeechEdu on June 25, 2026, widening its reach into education.

In July 2026 it worked with robot maker Clobot to install voice interfaces on about 20 guide robots at Incheon International Airport, and said the case would extend its business into physical AI areas such as robots and mobility.

On the medical side, integrated monitoring that links bedside biosignal data across a hospital is the core theme, and in July 2026 MEDIANA said it began cooperating with an AI semiconductor company and an AI robot company to build a hospital-type physical AI platform.

Combining AI software with hospital medical devices means growth depends on hospital spending and approval timelines. The company was added to the KOSDAQ 150 index in March 2026, and it said it expects passive fund inflows as a result.

Large IT platform companies often bundle voice AI into their own services, whereas Selvas AI sells its voice engines as solutions for specific verticals such as medical, e-books and finance, so the competitive picture differs.

In mobility, its areas may overlap with automotive software companies, so the speed at which it builds references matters.

06

Outlook

The direction the company has set out is to raise the revenue share of new businesses in 2026 and keep improving profitability through new product launches, as stated on February 20, 2026. This direction showed up in part in operating profit in the second and third quarters of 2026.

On the medical side, the company said in March 2026 that approvals for medical devices related to its MEDIANA-based central monitoring solution (CMS) were expected to be completed within the second quarter.

In the same statement it said it is developing various AI medical services starting with CMS and will release the solutions in sequence within 2026.

On the voice side, following the YES24 commercialization in November 2026, it plans to extend on-device speech synthesis to mobility, educational devices and smart appliances. MEDIANA has moved forward with linking medical AI algorithms after its cumulative integrated monitoring supply passed 6,000 beds.

SpeechEdu, launched in June 2026, was designed for institution-specific learning content, according to the company. What the company has announced is mainly directional, so whether approvals and product launches translate into revenue has to be checked against quarterly trends.

The pace at which the voice business gains revenue share and the trend in MEDIANA's overseas sales are the two pillars of the 2026 earnings recovery.

07

Valuation

PER
—
PBR
1.9×
ROE
-4.4%
EPS
-₩185
BPS
₩4,000
Dividend per share
₩0

Valuation has to be read against results from a loss-making stretch. Attributable net losses over the last four quarters (fourth quarter of 2025 through third quarter of 2026) total KRW 4.99 billion, so a price-to-earnings multiple cannot be calculated.

The price-to-book ratio is above 1x, which means the shares carry a premium over attributable net asset value. Attributable equity is less than half of total equity, so the non-controlling interest structure matters as well. Dividend-based comparison does not hold because the dividend yield is close to 0%.

Looking back, operating profit recovered from KRW 8 million in 2024 to KRW 1.48 billion in 2025, and quarterly operating profit turned positive in the second and third quarters of 2026.

Attributable net results have not yet shown a move to profit, so the valuation question centers on whether operating profit converts into attributable net profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Overseas growth at subsidiary MEDIANA

Subsidiary MEDIANA's 2025 revenue rose 13.6% to KRW 64.8 billion, and its operating profit grew 339.2% to KRW 5.65 billion. That year, North American sales of its patient monitors rose more than 60% and European sales of its AEDs rose more than 65%.

In the first half of 2026 MEDIANA reported consolidated revenue of KRW 37.2 billion and operating profit of KRW 4.6 billion, the highest first-half figures in three years, according to the company.

Operating profit in the black

Operating profit was positive at KRW 1.78 billion in the second quarter of 2026 and KRW 1.86 billion in the third, two quarters in a row. Third-quarter operating profit rose 79.8% year on year, and revenue of KRW 33.9 billion rose 31.4% from a year earlier. The move from an operating loss in the first quarter of 2026 to profit is the main positive.

Wider voice AI references

On November 11, 2026 the company commercialized on-device speech synthesis with automatic Korean-English switching in YES24's e-book app. In July 2026 it installed voice interfaces on about 20 guide robots at Incheon International Airport.

Its voice references are expanding into e-books, airports and financial kiosks, diversifying its application base.

09

Bear factors

Three straight years of net losses

Attributable net losses were KRW 2.55 billion in 2023, KRW 5.81 billion in 2024 and KRW 6 billion in 2025, three consecutive years of losses. Losses continued in the second and third quarters of 2026, and the third-quarter net loss of KRW 1.15 billion marked a swing to loss from a year earlier.

Over the four quarters from the fourth quarter of 2025 through the third quarter of 2026, attributable net losses totaled KRW 4.99 billion, so operating profit has not carried through to the bottom line.

Operating margin stuck near 1%

The operating margin fell from 9.8% in 2022 to 0.7% in 2024 and was still only 1.3% in 2025. Revenue rose just 2.1% in 2025, so top-line growth did not translate into margin improvement.

Annual profitability remains around 1% for 2025, and whether the quarterly profits become an annual trend has to be checked in the 2026 annual report.

Volatile quarterly results

Revenue fell 22.8% from the prior quarter to KRW 26.6 billion in the first quarter of 2026, with an operating loss of KRW 370 million. In the fourth quarter of 2025 attributable results swung to a net loss of KRW 3.71 billion from a profit in the prior quarter.

In the first half of 2025 the company said higher R&D spending for new products, currency losses and valuation losses on investment assets weighed on results.

10

Risk factors

Dependence on subsidiary results

The company cited MEDIANA's overseas sales and cost structure as the drivers of 2025 operating profit growth, so consolidated results lean heavily on the subsidiary. Swings in North American and European sales, the timing of approvals in the Middle East and currency moves could all shake consolidated earnings. A shift to attributable net profit also depends on this trend.

Approval and regulatory timing

If approvals for medical devices such as CMS are delayed, revenue from integrated monitoring could slip. Tighter rules on medical data and personal information could affect how quickly voice recording and monitoring services are adopted. Hospital adoption follows contract timing, which can add to quarter-to-quarter volatility.

Technology shifts and reliance on external models

Voice AI is changing quickly as it combines with large language models. The company uses external models such as GPT, Gemini and Claude, so changes in their pricing or terms could affect its costs and features.

Its consolidated revenue is small next to large IT groups, which could constrain its room to invest in the technology race.

11

What to watch next

  1. By year-end 2026

    Whether the AI medical services the company said in March 2026 would be released in sequence within the year actually launch, and how many hospitals adopt them. A launch would confirm the shift in the medical platform business.

  2. Around February 2027

    The preliminary full-year 2026 results. The company released preliminary 2025 results on February 20, 2026, so a similar timing is expected. The direction of operating profit and attributable net results is the focus.

  3. By March 31, 2027

    The filing of the 2026 annual report on DART. It is the checkpoint for confirmed full-year results including the fourth quarter, the annual operating margin, whether attributable net losses continue, and changes in the capital structure.

  4. By May 15, 2027

    Operating profit and attributable net results in the first-quarter 2027 report. It will show whether the operating profits seen in the second and third quarters of 2026 continue quarter to quarter.

12

Overall view

Selvas AI's 2025 revenue of KRW 114.8 billion rose for three consecutive years, with overseas sales growth at subsidiary MEDIANA supporting the top line. Operating profit recovered from KRW 8 million in 2024 to KRW 1.48 billion in 2025, but the operating margin was still only 1.3% in 2025.

Attributable net losses have continued for three consecutive years since 2023, and the second and third quarters of 2026 showed net losses despite operating profit.

Third-quarter 2026 revenue of KRW 33.9 billion and operating profit of KRW 1.86 billion rose 31.4% and 79.8% from a year earlier, so the quarterly direction is improving. The voice AI business is adding references through the YES24 on-device speech synthesis launch and the Incheon airport guide robot.

The points to check are whether 2026 full-year operating profit converts into attributable net profit, and whether the operating margin in the 2026 annual report moves above 1%.

Progress on MEDIANA's integrated monitoring, CMS approvals and the release of AI medical services within 2026 are also checkpoints for the structural shift. This report does not present an investment opinion, rating or target price, and figures are based on DART periodic filings and company announcements.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. selvasai.com
  2. comp.wisereport.co.kr
  3. selvasai.com
  4. hitnews.co.kr
  5. hankyung.com
  6. technovalue.com
  7. sedaily.com
  8. selvasai.com
  9. v.daum.net
  10. selvasai.com
  11. bosa.co.kr
  12. aitimes.kr
  13. mt.co.kr
  14. investing.com
  15. medicaltimes.com
  16. alphasquare.co.kr
  17. newspim.com
  18. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis